Femasys (NASDAQ:FEMY) Earns Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Femasys (NASDAQ:FEMY) in a report published on Wednesday morning,Benzinga reports. The firm currently has a $12.00 price target on the stock.

Separately, Jones Trading dropped their price objective on shares of Femasys from $10.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, May 13th.

Femasys Stock Down 4.4%

Femasys stock opened at $0.89 on Wednesday. The stock has a market capitalization of $22.72 million, a PE ratio of -1.10 and a beta of -2.62. Femasys has a twelve month low of $0.69 and a twelve month high of $1.80. The company has a quick ratio of 3.26, a current ratio of 3.94 and a debt-to-equity ratio of 0.86. The company has a 50 day moving average of $1.06 and a 200-day moving average of $1.20.

Femasys (NASDAQ:FEMY) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.06). Femasys had a negative return on equity of 141.49% and a negative net margin of 1,435.77%. The firm had revenue of $0.34 million for the quarter, compared to the consensus estimate of $1.14 million. On average, equities research analysts anticipate that Femasys will post -0.86 EPS for the current fiscal year.

Institutional Trading of Femasys

Several hedge funds have recently modified their holdings of the stock. Dauntless Investment Group LLC purchased a new position in Femasys during the 1st quarter worth $1,969,000. Clear Creek Financial Management LLC boosted its holdings in Femasys by 5.5% during the 1st quarter. Clear Creek Financial Management LLC now owns 270,371 shares of the company’s stock worth $338,000 after acquiring an additional 14,000 shares during the last quarter. Citadel Advisors LLC purchased a new position in shares of Femasys in the 4th quarter worth about $45,000. Jane Street Group LLC purchased a new position in shares of Femasys in the 4th quarter worth about $30,000. Finally, Northern Trust Corp boosted its holdings in shares of Femasys by 42.6% in the 4th quarter. Northern Trust Corp now owns 126,096 shares of the company’s stock worth $139,000 after buying an additional 37,675 shares during the last quarter. Institutional investors own 65.27% of the company’s stock.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.